Focal Adhesion Kinase: A promising therapeutic target in pancreatic adenocarcinoma
- PMID: 27939096
- DOI: 10.1016/j.clinre.2016.10.010
Focal Adhesion Kinase: A promising therapeutic target in pancreatic adenocarcinoma
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains a deadly cancer, characterized by a uniquely immunosuppressive and fibrotic microenvironment responsible for its high chemoresistance. Jiang et al. identify FAK (focal adhesion kinase) activity as an interesting therapeutic target, the inhibition of which drastically reduces PDAC microenvironment deleterious features. In combination with gemcitabine and immune-checkpoint therapy, FAK inhibitor promotes long-term tumor stasis with extended survival in PDAC mouse models. In conclusion, Jiang et al. provide proof of concept that FAK inhibitors combined with chemotherapy will highly profit PDAC patients.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.
Comment on
-
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.Nat Med. 2016 Aug;22(8):851-60. doi: 10.1038/nm.4123. Epub 2016 Jul 4. Nat Med. 2016. PMID: 27376576 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous